INTRODUCTION
deaths, Lung cancer, nonsquamous NSCLC, tumor
LUNG CANCER, TUMOR
Lung cancer is the most common cause of cancer‐related deaths worldwide.Vascular endothelial growth factor (VEGF) is the central mediator of angiogenesis, the development of new blood vessels, a process that is vital for tumor cell growth.BAT1706 is a recombinant humanized anti‐VEGF monoclonal antibody developed by Bio‐Thera Solutions, Ltd. as a proposed biosimilar of bevacizumab to meet the need for alternatives to expensive biologic agents. A biosimilar is a biological product that is highly similar to, and has no clinically meaningful differences from, an existing approved reference biologic.Two Phase I clinical studies conducted in New Zealand (NCT03030430) and China (BAT1706‐002‐CR) demonstrated that a single intravenous infusion of BAT1706 (1 mg/kg) was well‐tolerated in healthy participants.In this pivotal Phase III study (NCT03329911), we compared the efficacy and safety of BAT1706 and EU‐bevacizumab, given in combination with chemotherapy, as first‐line treatment for advanced nonsquamous NSCLC, in order to evaluate the clinical equivalence of BAT1706 and reference EU‐bevacizumab.